Insider Buys 62,000 Shares of C4 Therapeutics, Inc.
Ronald Cooper acquired 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026.
Key Points
- Ronald Cooper purchased 62,000 shares of C4 Therapeutics, Inc. (CCCC) on June 24, 2026.
- Shares of C4 Therapeutics traded near $4.26 on Saturday with a market cap of about $471 million.
- Analysts maintain a strong buy consensus with a mean price target of $13.33.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Ronald Cooper, an insider at C4 Therapeutics, Inc., bought 62,000 shares of the company. This transaction occurred without any pre-planned trading scheme and added to the insider activity in the biotech firm.
Insider Buying and Selling at C4 Therapeutics, Inc.
Several insiders at C4 Therapeutics, including Steven Hoerter, Utpal Koppikar, Laura Bessen, Stephen Fawell, and Owen Hughes, also purchased 62,000 shares each on the same day as Cooper. These transactions were not part of a Rule 10b5-1 plan.
C4 Therapeutics, Inc. Stock Up 10.6%
Shares of NasdaqGS:CCCC traded near $4.26 on Saturday. C4 Therapeutics, Inc. has a market cap of approximately $471 million and a forward P/E ratio that isn't meaningful because it isn't profitable. The stock has experienced a 52-week low of $1.40 and a high of $4.60. With a 50-day moving average of $3.51 and a 200-day moving average of $2.70, the company's beta stands at 2.93, indicating higher volatility compared to the broader market.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analyst firms have recently maintained their positive outlook on C4 Therapeutics. On June 1, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $12. Barclays has consistently kept a 'buy' rating, with a range of price targets, the latest being $7 on February 27, 2026. Overall, the consensus among analysts is a strong buy, with a mean target price of $13.33.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing therapies that degrade harmful proteins to treat diseases. The company’s lead candidate, Cemsidomide, targets multiple myeloma and has completed phase 1 trials. C4 Therapeutics is also working on other products for oncology and inflammation, with strategic partnerships with companies like Roche and Merck. Led by CEO Andrew J. Hirsch, the company employs 104 people.
Bottom Line
Insider buying at C4 Therapeutics highlights confidence in the company's future prospects. Investors watch these transactions closely as they can indicate management's belief in the company's potential. However, it's important to remember that insider activity is just one piece of the puzzle. Analyst ratings and market conditions also play significant roles in evaluating a stock's potential.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.